Drugs that contain Vortioxetine Hydrobromide

1. List of Trintellix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(3 years from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476279 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Oct, 2022

(3 months ago)

US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US11458134 TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(4 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Jan 22, 2024

Market Authorisation Date: 30 September, 2013

Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Use of trintellix for the treatment of major depressive disorder (mdd) in adults; Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

How can I launch a generic of TRINTELLIX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in